Company profile for Checkmate Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Checkmate Pharmaceuticals is a clinical stage company pursuing a novel approach to specifically activating the innate and adaptive arms of the immune system to recognize and ultimately destroy tumor cells. The company is leveraging its extensive expertise and experience in the field of CpG oligonucleotides (ODN) to evaluate the ability of CMP-001 (a CpG-A ODN) to stimulate an anti-tumor T cell response in combination with chec...
Checkmate Pharmaceuticals is a clinical stage company pursuing a novel approach to specifically activating the innate and adaptive arms of the immune system to recognize and ultimately destroy tumor cells. The company is leveraging its extensive expertise and experience in the field of CpG oligonucleotides (ODN) to evaluate the ability of CMP-001 (a CpG-A ODN) to stimulate an anti-tumor T cell response in combination with checkpoint inhibition to overcome a tumor’s ability to suppress the immune response. CMP-001 is the only CpG-A in clinical development.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1 Broadway, 14th Floor Cambridge, MA, 02142
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2022/09/15/2516893/0/en/Longeveron-Names-Jerome-Bailey-Vice-President-of-Business-Operations.html

GLOBENEWSWIRE
15 Sep 2022

https://www.prnewswire.com/news-releases/regeneron-completes-acquisition-of-checkmate-pharmaceuticals-301557792.html

PRNEWSWIRE
31 May 2022
Checkmate details troubled future if Regeneron deal fails
Checkmate details troubled future if Regeneron deal fails

14 May 2022

// A. Armstrong FIERCEBIOTECH

https://www.fiercebiotech.com/biotech/checkmate-details-troubled-future-if-250m-regeneron-merger-does-not-close

A. Armstrong FIERCEBIOTECH
14 May 2022

https://www.globenewswire.com/news-release/2022/05/12/2442540/0/en/Checkmate-Pharmaceuticals-Announces-First-Quarter-2022-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
12 May 2022

https://www.biopharmadive.com/news/regeneron-checkmate-cancer-drug-first-acquisition/622306/

J. Bell BIOPHARMADIVE
20 Apr 2022

https://www.globenewswire.com/news-release/2022/04/08/2419459/0/en/Checkmate-Pharmaceuticals-Presents-Clinical-Trial-Biomarker-Data-with-Vidutolimod-at-the-2022-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html

GLOBENEWSWIRE
08 Apr 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty